Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097457 | 0.85 | KMT2A (0.37) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL23226887 | 0.82 | ALDH1A1 (0.39) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL178300 | 0.79 | KMT2A (0.44) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL6044102 | 0.78 | KMT2A (0.42) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL356238 | 0.77 | KMT2A (0.38) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL479863 | 0.77 | ALOX15 (0.57) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL1099428 | 0.77 | KMT2A (0.38) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL22025526 | 0.77 | KMT2A (0.42) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL898008 | 0.77 | ALDH1A1 (0.43) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL9157084 | 0.77 | KMT2A (0.42) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023139085-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | claimed |
| US-9724333-B2 | Pyrazole derivative | GREEN TECH CO., LTD. (JP) | 2017-08-08 | — | — | US | claimed |
| US-20160228412-A1 | NOVEL PYRAZOLE DERIVATIVE | GREEN TECH CO., LTD. (JP) | 2016-08-11 | — | — | US | claimed |
| US-9321752-B2 | Pyrazole derivative | GREEN TECH CO., LTD. (JP) | 2016-04-26 | — | — | US | claimed |
| US-20150252029-A1 | Novel Pyrazole Derivative | GREEN TECH CO., LTD. (JP) | 2015-09-10 | — | — | US | claimed |
| EP-2907805-A1 | NOVEL PYRAZOLE DERIVATIVE | Green Tech Co., Ltd. (JP) | 2015-08-19 | — | — | EP | claimed |
| EP-2507210-B1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | NOVARTIS AG (CH) | 2015-04-08 | — | — | EP | claimed |
| US-8394858-B2 | Cyclohexane derivatives and uses thereof | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | claimed |
| EP-2507210-A1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | Novartis AG (CH) | 2012-10-10 | — | — | EP | claimed |
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | claimed |
| WO-2001094341-A9 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2003-04-17 | — | — | WO | claimed |
| EP-1292594-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | AstraZeneca AB (SE) | 2003-03-19 | — | — | EP | claimed |
| WO-2002092577-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | claimed |
| WO-2002085895-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | claimed |
| EP-1218353-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca UK Limited (GB) | 2002-07-03 | — | — | EP | claimed |
| WO-2002034744-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-05-02 | — | — | WO | claimed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | claimed |
| WO-2001094341-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | WO | claimed |
| WO-2001004102-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-01-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228412-A1 | NOVEL PYRAZOLE DERIVATIVE | PSEN2, PSEN1, MAPT | KMT2A 3488/4885MEN1 4329/4885CYP2C19 3901/4885 |
| US-20150252029-A1 | Novel Pyrazole Derivative | PSEN2, PSEN1, MAPT | KMT2A 3488/4885MEN1 4329/4885CYP2C19 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.